MaxCyte
MXCT
120 hedge funds and large institutions have $331M invested in MaxCyte in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 49 increasing their positions, 30 reducing their positions, and 20 closing their positions.
65% more capital invested
Capital invested by funds: $201M → $331M (+$130M)
63% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 30
5.74% more ownership
Funds ownership: 62.17% → 67.91% (+5.7%)
0% more funds holding
Funds holding: 120 → 120 (0)
0% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 20
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $21K
Top Buyers
| 1 |
CCM
Cadian Capital Management
New York
|
+$22M |
| 2 |
Morgan Stanley
New York
|
+$21.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$11M |
| 4 |
Millennium Management
New York
|
+$4.54M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$2.39M |
Top Sellers
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$11.7M |
| 2 |
Holocene Advisors
New York
|
-$6.61M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$6.32M |
| 4 |
CC
Casdin Capital
New York
|
-$5.9M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$4.03M |
MXCT Hedge Fund Activity: Q4 2023 in Review
120 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q4 2023, worth a combined $331M — up 65% from $201M a quarter earlier.
Fund positioning in MXCT was balanced in Q4 2023: 20 funds opened new positions, 20 closed out, 49 added to existing stakes and 30 trimmed.
The largest buyer was Cadian Capital Management, opening a new position worth an estimated $22M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $11.7M sold.
- 120 institutional investors held MaxCyte (MXCT) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $331M of MaxCyte stock for Q4 2023, up 65% quarter-over-quarter.
- 20 funds opened new MaxCyte positions in Q4 2023 and 20 closed out, a net change of 0 holders.
- The largest MaxCyte buyer in Q4 2023 was Cadian Capital Management, an estimated $22M added.
- The largest MaxCyte seller in Q4 2023 was Stonepine Capital Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q4 2023.